已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

CheckpointPx: A predictive radiology AI model of immune checkpoint inhibitor (ICI) benefit in non-small cell lung cancer (NSCLC).

医学 肺癌 肿瘤科 癌症研究 癌症 内科学 免疫系统 肺 免疫学
作者
Seyoung Lee,Amogh Hiremath,Jeeyeon Lee,Haseok Kim,Kai Zhang,Salie Lee,Monica Yadav,Liam IL Young Chung,Hye Sung Kim,Trie Arni Djunadi,Yuchan Kim,Ilene Hong,Grace Kang,Amy Cho,Yury Velichko,Amit Gupta,Vamsidhar Velcheti,Anant Madabhushi,Nathaniel Braman,Young Kwang Chae
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): 8632-8632
标识
DOI:10.1200/jco.2024.42.16_suppl.8632
摘要

8632 Background: Immune checkpoint inhibitors (ICIs) have dramatically transformed the field of non-small cell lung cancer (NSCLC) treatment. Despite the widespread use of PD-L1 as a biomarker in NSCLC, it has significant limitations as a reliable predictive biomarker for ICI response. Addressing this limitation, we have developed CheckpointPx, a non-invasive radiology AI tool to assist in ICI treatment selection for patients using only baseline CT scans. Here we demonstrate that CheckpointPx can predict improved outcomes specific to treatment with ICIs, presenting a new tool to address the shortage of reliable predictive ICI biomarkers in NSCLC and ultimately improve outcomes for patients undergoing immunotherapeutic interventions. Methods: CheckpointPx (v1.11) was trained on pre-treatment CT scans to predict response to ICIs from training data (D1: n=252 ICI recipients) from three institutions (A-C). In this study, we evaluated its performance in predicting response in two validation cohorts: a Treatment Dataset of patients receiving immunotherapy (D2: n=224, institutions B-D) and a Control Dataset of patients receiving platinum-based chemotherapy alone (D3: n=76, institution B). The response was defined as disease control per RECIST v1.1. Experienced radiologists and physicians delineated target lesions, and a deep learning model segmented pulmonary vessels. From these segmented regions, radiomic features were extracted using the Picture Health Px platform and were used to generate a radiomics benefit score and corresponding benefit groups using D1. The ability of benefit groups to stratify patients by progression-free survival (PFS) was compared across D2 and D3 to evaluate its utility in identifying patients who would benefit from ICI over chemotherapy. Results: D2 and D3 contained a mix of treatment lines (1st-4th) and predominantly late-stage tumors (Stage 3/4, >85%). CheckpointPx included 16 features, such as measurements of intra-tumoral heterogeneity and vessel twistedness and branching patterns. Within the treatment dataset (D2), CheckpointPx was found to significantly stratify ICI patients by progression-free survival (PFS) with HR=0.68 (95% CI: 0.52 - 0.93, p=0.019). When applied to the control dataset, D3, benefit groups failed to stratify patients treated with chemotherapy by outcome (HR=0.91 [95% CI: 0.51-1.61], p=0.740), indicating that the signature was specific to ICI response. Conclusions: CheckpointPx demonstrated the ability to identify NSCLC patients who would benefit from ICI over chemo. The model’s association with PFS among ICI recipients, but not patients receiving chemotherapy alone, suggests that the signature is predictive of immunotherapy-related outcomes rather than generally prognostic. Additional independent, multi-site and prospective validation is warranted.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wesley完成签到 ,获得积分10
刚刚
王化省完成签到,获得积分10
3秒前
彭于晏的应助被气球好饿采纳,获得10
4秒前
8秒前
Milton_z完成签到 ,获得积分0
9秒前
学霸业的应助被DW采纳,获得10
9秒前
华仔的应助被微山采纳,获得10
9秒前
10秒前
11秒前
cjg完成签到 ,获得积分10
12秒前
Rebirth发布了新的文献求助10
12秒前
meow完成签到 ,获得积分10
13秒前
机智的如曼完成签到,获得积分10
13秒前
哦哦哟完成签到 ,获得积分10
13秒前
Lw完成签到,获得积分10
15秒前
汪汪完成签到 ,获得积分10
15秒前
跳不起来的大神完成签到 ,获得积分10
16秒前
花落雨凇的应助被邢绿凝采纳,获得10
16秒前
可爱的函函的应助被Gari采纳,获得10
17秒前
zzz完成签到 ,获得积分10
18秒前
Dao完成签到 ,获得积分10
19秒前
七七完成签到 ,获得积分10
19秒前
瑩火虫完成签到 ,获得积分10
19秒前
mingming完成签到 ,获得积分10
21秒前
molihuakai的应助被石永怡采纳,获得10
21秒前
学霸业的应助被DW采纳,获得10
22秒前
背后的尔琴完成签到 ,获得积分10
22秒前
alvinw完成签到,获得积分10
23秒前
23秒前
芒果完成签到 ,获得积分10
24秒前
xzp完成签到,获得积分10
25秒前
知北游完成签到 ,获得积分10
25秒前
cen关闭了cen的文献求助
27秒前
深情安青的应助被邢绿凝采纳,获得10
28秒前
29秒前
Lan完成签到 ,获得积分10
30秒前
30秒前
31秒前
糖豆完成签到,获得积分10
31秒前
光亮的小甜瓜完成签到 ,获得积分10
33秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184764
求助须知:如何正确求助?哪些是违规求助? 9573733
关于积分的说明 21832921
捐赠科研通 7782115
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558528
邀请新用户注册赠送积分活动 2481067